Yes, the company announced the answer to your question months ago. Please read the company's previous press releases.
A second, independently conducted study to evaluate preventive efficacy and efficacy against a controlled exposure to a known rhinovirus was supposed to have been completed by the end of October.
Since neither GelTech nor GUMM participated in the data collection or the experiments themselves, they are not responsible for the write-up.
Assuming that the studies are indeed completed and that the people who run these entities are both smart and want to see these results made public ASAP, it is reasonable to expect that they will do what they did with the first study (viz., submit an abstract, make a presentation or poster at a medical meeting) so as to enable publicity of those results during the present major rollout of the product. It is the potential of those study results that also makes this stock a very stupid short sale at this time. Imagine all the free publicity (twice what you see now, I am sure) that will occur if preventive efficacy is demonstrated. Think of all the people who will, for just one example, take Zicam before getting on their airline flights.
Despite the complete BS ramblings of an utter moron short on the SI boards, GUMM executives are interested in selling quality products, not their stock.
Most of us who have been posting about this company are not "trading" it, we are investing in it for the long haul because of the potential of their products in relation to their present market cap. In other words, we are getting in on the major phase (or first phases) of growth. |
